Genetic susceptibility to macrovascular complications of type 2 diabetes mellitus

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 15, Issue 3, 2001, Pages 359-370

  Barakat, K ^a   Hitman, G A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Candidate genes; Genetic; Ischaemic heart disease; Macrovascular complications; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSINOGEN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BETA ADRENERGIC RECEPTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; GELATINASE B; GLYCOPROTEIN IIIA; HORMONE RECEPTOR; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; STROMOLYSIN; THROMBOMODULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; DEATH; DIABETES CONTROL; DISEASE PREDISPOSITION; FAMILY; GENE; GENETIC ANALYSIS; GENETIC PROCEDURES; GENETIC SUSCEPTIBILITY; GLYCATION; HEMOSTASIS; HERITABILITY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MULTIFACTORIAL INHERITANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; SMOKING; VASCULAR DISEASE;

EID: 0034807959     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2001.0151     Document Type: Article

References (67)

1. Genetics of diabetic complications
2. Atherosclerosis
3. Role of hemostatic polymorphisms in venous and arterial thrombotic disease
4. Plasma lipoproteins: Apolipoprotein structure and function
5. The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and function
6. Recombinant apolipoproteins for the treatment of vascular diseases
7. The plasma lecithin: Cholesterol acyltransferase reaction
8. High density lipoprotein: The clinical implication of recent studies
9. Lecithin-cholesterol acyltransferase in the metabolism of high density lipoproteins
10. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux
11. Inhibition of early atherosclerosis in transgenic mice by human Apo A-1
12. Apolipoprotein A-1 transgene corrects Apo E deficiency in mice
13. Inhibition of atherosclerosis development in cholesterol fed human apolipoprotein A-1 transgenic rabbits
14. Effects of adenovirus mediated human Apo A-1 gene transfer on neointimal formation after endothelial denudation in Apo E deficient mice
15. Mspl polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease
16. Plasma lipoproteins: Apolipoprotein structure and function
17. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3
18. Apolipoprotein E inhibition of proliferation of mitogen activated T lymphocytes: Production of interleukin 2 with reduced biological activity
19. Apolipoprotein E inhibits interleukin dependent T lymphocyte proliferation at the G1A/G1B boundary
20. Apolipoprotein E: A potent inhibitor of endothelial and tumour cell proliferation
21. Apolipoprotein E inhibits platelet aggregation through the L-arginine-nitric oxide pathway. Implications for vascular disease
22. Atherosclerosis in mice lacking Apo E. Evaluation of lesional development and progression
23. Apo E deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
24. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele
25. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: Influence of apolipoprotein E polymorphism
26. Relation of coronary heart disease and apolipoprotein phenotype in patients with non-insulin dependent diabetes
27. The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study IX
28. Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects
29. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis
30. Lipoprotein physiology in nondiabetic and diabetic states: Relationship to atherogenesis
31. Lipoprotein gene variants and risk of coronary artery disease: A quantitative analysis of population based studies
32. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolaemia
33. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study
34. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: The European Atherosclerosis Research Study (EARS)
35. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
36. Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention
37. DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro- and microangiopathy in non-insulin-dependent diabetes mellitus
38. Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients
39. Angiotensin-convering enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years
40. The role of oxidized lipoprotein in atherogenesis
41. Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes
42. Glycosylation of LDL enhances cholesteryl ester synthesis in human monocyte-derived macrophages
43. Oxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose
44. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway
45. Lipid advance glycosylation: Pathway for lipid oxidation in vivo
46. Oxygen metabolism and the toxic properties of phagocytes
47. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor
48. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
49. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients
50. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators
51. Mutations in the human paraoxonase I gene: Frequencies, allelic linkages, and association with coronary artery disease
52. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
53. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
54. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction
55. Angiotensin 1-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM
56. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
57. Peroxisome proliferator-activated receptor gamma C161T polymorphism and coronary artery disease
58. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease
59. Thrombi in acute coronary syndromes: Revisited and revised
60. Genetic determinants of arterial thrombosis
61. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes
62. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy
63. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
64. Factors of the haemostatic system in diabetic patients
65. Covalent structure of fibrinogen
66. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM
67. Beta-fibrinogen gene G/A-455 polymorphism in relation to fibrinogen concentrations and ischaemic heart disease in Chinese patients with type II diabetes